Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 8/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.52 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.52 |
| ▸ | GRM3 | Q14832 | 3/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | GRM8 | O00222 | 2/20 | 0.52 |
| ▸ | GRM6 | O15303 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | GRM5 | P41594 | 1/20 | 0.52 |
| ▸ | MTOR | P42345 | 1/20 | 0.52 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.52 |
| ▸ | PLCB1 | Q9NQ66 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14372097 | 1.00 | GRM4 (0.52) | GRM4CYP1A2CYP2C19GRM2GRM3 | |
| SCHEMBL8179890 | 1.00 | GRM4 (0.52) | GRM4CYP1A2CYP2C19GRM2GRM3 | |
| Hydrochloric Acid SCHEMBL28534660 | 0.98 | GRM4 (0.50) | GRM4CYP1A2CYP2C19GRM2GRM3 | |
| SCHEMBL31415502 | 0.92 | GRM4 (0.46) | GRM4CYP1A2CYP2C19GRM2GRM3 | |
| SCHEMBL31415320 | 0.92 | GRM4 (0.46) | GRM4CYP1A2CYP2C19GRM2GRM3 | |
| SCHEMBL2898361 | 0.86 | GRM4 (0.59) | GRM4CYP1A2CYP2C19GRM2GRM3 | |
| SCHEMBL912861 | 0.78 | GRM4 (0.54) | GRM4CYP1A2CYP2C19GRM2GRM3 | |
| SCHEMBL544530 | 0.78 | GRM4 (0.54) | GRM4CYP1A2CYP2C19GRM2GRM3 | |
| SCHEMBL5007909 | 0.78 | GRM4 (0.54) | GRM4CYP1A2CYP2C19GRM2GRM3 | |
| SCHEMBL5007910 | 0.78 | GRM4 (0.54) | GRM4CYP1A2CYP2C19GRM2GRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11970495-B2 | Indolizine derivatives and their application in medicine | KIND PHARMACEUTICAL (CN) | 2024-04-30 | — | — | US | disclosed |
| US-11945817-B2 | Indolizine derivatives and their application in medicine | KIND PHARMACEUTICAL (CN) | 2024-04-02 | — | — | US | disclosed |
| US-20230257379-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230242527-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2023-08-03 | — | — | US | disclosed |
| US-11655249-B2 | Indolizine derivatives and their application in medicine | KIND PHARMACEUTICAL (CN) | 2023-05-23 | — | — | US | disclosed |
| WO-2023081730-A1 | 4-HYDROXY-2-OXO-1,2-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXAMIDE DERIVATIVES AS CANNABINOID CB2 RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER | TEON THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| EP-3613742-B1 | INDOLIZINE DERIVATIVES AND APPLICATION THEREOF IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2022-12-07 | — | — | EP | disclosed |
| CN-108727468-B | Cyclic peptide, pharmaceutical or cosmetic composition comprising the same, and preparation method thereof | 陈建添 | 2021-12-03 | — | — | CN | disclosed |
| EP-3628677-B1 | METHOD FOR PREPARING A CYCLOPEPTIDE | UNIV NAT TSING HUA (TW) | 2021-11-10 | — | — | EP | disclosed |
| US-20210253570-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2021-08-19 | — | — | US | disclosed |
| US-6140358-A | FOR CONTROLLING PESTS AND WEEDS | BAYER AKTIENGESELLSCHAFT (DE) | 2000-10-31 | — | — | US | disclosed |
| US-5965579-A | ANTAGONISTS OF THE NEUROTENSIN RECEPTORS; INCREASING AFFINITY FOR HUMAN NEUROTENSIN RECEPTORS | SANOFI (FR) | 1999-10-12 | — | — | US | disclosed |
| US-5939449-A | NOVEL COMPOUNDS HAVING HIGH AFFINITY FOR THE NEUROTENSIN RECEPTORS | SANOFI (FR) | 1999-08-17 | — | — | US | disclosed |
| US-5936123-A | COMPOUNDS SUCH AS 3-ISOPROPYL-4-HYDRAZINOBENZOIC ACID AND ITS SALTS | SANOFI (FR) | 1999-08-10 | — | — | US | disclosed |
| US-5925661-A | NERVOUS SYSTEM DISORDERS | SANOFI (FR) | 1999-07-20 | — | — | US | disclosed |
| WO-1999032488-A1 | METHOD FOR PREPARING A HYDANTOIN DERIVATIVE SUBSTITUTED IN POSITION 5, METHOD FOR PREPARING AN α-AMINO ACID ALKALINE SALT FROM SAID HYDANTOIN DERIVATIVE AND METHOD FOR ESTERIFYING CYCLIC α-AMINO ACIDS | SERANALIS (FR) | 1999-07-01 | — | — | WO | disclosed |
| US-5723483-A | NEUROTENSIN ANTAGONIST, HYPOTENSIVE AGENTS AND FOR NEUROPSYCHIATRIC DISORDERS | SANOFI (FR) | 1998-03-03 | — | — | US | disclosed |
| US-5585497-A | USEFUL IN TREATMENT OF NEUROPSYCHIATRIC DISORDERS, ESPECIALLY THOSE ASSOCIATED WITH A DYSFUNCTION OF THE DOPAMINERGIC SYSTEMS | SANOFI (FR) | 1996-12-17 | — | — | US | disclosed |
| US-5523455-A | PREPARED USING A NAPHTHYLHYDRAZINE CHEMICAL INTERMEDIATE | SANOFI (FR) | 1996-06-04 | — | — | US | disclosed |
| US-5502059-A | DOPAMINERGIC DYSFUNCTION DISORDERS | SANOFI (FR) | 1996-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257379-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | INMT, IDO1, IDO2 | GRM4 1294/4885CYP1A2 72/4885CYP2C19 40/4885 |
| US-11970495-B2 | Indolizine derivatives and their application in medicine | INMT, IDO1, IDO2 | GRM4 1294/4885CYP1A2 72/4885CYP2C19 40/4885 |
| US-20230242527-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | INMT, IDO1, IDO2 | GRM4 1294/4885CYP1A2 72/4885CYP2C19 40/4885 |
| US-11945817-B2 | Indolizine derivatives and their application in medicine | INMT, IDO1, IDO2 | GRM4 1294/4885CYP1A2 72/4885CYP2C19 40/4885 |
| US-20210253570-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | INMT, IDO1, IDO2 | GRM4 1294/4885CYP1A2 72/4885CYP2C19 40/4885 |
| US-11655249-B2 | Indolizine derivatives and their application in medicine | INMT, IDO1, IDO2 | GRM4 1294/4885CYP1A2 72/4885CYP2C19 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.